

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-20 (**Cancelled**)

21. (**Currently amended**) A method for identifying an ~~anti-cancer~~ cancer therapeutic agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:

contacting a candidate ~~anti-cancer~~ agent with a cell that expresses DKFZp5661133; and

detecting a difference between the biological activity of DKFZp5661133 in the presence and absence of the candidate ~~anti-cancer~~ agent,

wherein a difference between the level of biological activity of DKFZp5661133 in the presence and absence of the candidate anti-cancer agent indicates that the candidate ~~anti-cancer~~ agent ~~has anti-cancer activity~~ is a cancer therapeutic.

22. (**Original**) The method of claim 21, wherein said cancerous cell and said normal cell are breast cells.

23. (**Previously presented**) The method of claim 21, wherein said detecting is by assessing expression of said gene product.

24. (**Original**) The method of claim 23, wherein expression is assessed by detecting a polynucleotide gene product.

25. (**Previously presented**) The method of claim 23, wherein expression is assessed by detecting a polypeptide gene product.

26. (**Previously presented**) The method of either of claim 21 or claim 32, wherein said candidate agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

27. **(Previously presented)** The method of claim 21, wherein said biological activity is modulation of a cancerous phenotype.

28. **(Original)** The method of claim 27, wherein said cancerous phenotype is abnormal cellular proliferation.

29. **(Previously presented)** The method of claim 27, wherein said cancerous phenotype is loss of contact inhibition.

30. **(Cancelled)**

31. **(Previously presented)** The method of either of claim 21 or claim 32 wherein the agent is a DKFZ antisense polynucleotide which inhibits DKFZ gene expression by at least 90%.

32. **(Currently amended)** A method of screening a candidate agent ~~for anti-cancer activity~~ to identify a cancer therapeutic comprising:

(a) contacting a cell that expresses DKFZp5661133 with a candidate agent; and

(b) detecting a difference between the level of expression of DKFZp5661133 in the presence and absence of the candidate agent, wherein a difference between the level of DKFZp5661133 expression in the presence and in the absence of the candidate agent indicates that the candidate agent ~~has anti-cancer activity~~ is a cancer therapeutic.

33. **(Previously presented)** The method of claim 32 wherein a difference in expression levels of DKFZp5661133 is detected using a polymerase chain reaction, hybridization, or Western blot.

34. **(Previously presented)** The method of either of claims 21 or 32 wherein the cancer is breast cancer.

35. **(Previously presented)** The method of claim 31 wherein the DKFZ antisense polynucleotide comprises a nucleotide sequence comprising at least 12 contiguous nucleotides of SEQ ID NO:513, or complement thereof.

36. **(Previously presented)** The method of claim 31 wherein the DKFZ antisense polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:508 and SEQ ID NO:510.

37. **(Previously presented)** The method of claim 21 wherein the biological activity is selected from the group consisting of cell growth, proliferation and invasiveness.

38. **(New)** The method of claim 21 wherein the cancerous cell and said normal cell are other than breast cancer cells.

39. **(New)** The method of claim 21 or 32 wherein the cancer is other than breast cancer.